EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review

Effrosyni Blathra, Evangelos Liberopoulos

Journal of Atherosclerosis Prevention and Treatment · 2025-07 · 16 (3) · 93-98

DOI: 10.4103/aptj.aptj_16_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Atherosclerosis Prevention and Treatment, online erschienen am 26.02.2026. Verfasst von Effrosyni Blathra und 1 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide is a dual glucagon-like peptide-1/glucose-dependent insulinotropic peptide receptor agonist consisting one of the latest therapeutic options for diabetes and obesity. Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly frequent medical entity, possibly leading to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and cirrhosis. MASLD management is primarily based on weight loss and physical exercise. A number of randomized controlled trials (RCTs) with tirzepatide have been conducted in people with histologically-proven MASH and showed beneficial effects. Herein, we briefly review available evidence for the effects of tirzepatide on MASLD.

Zitieren

APA

Blathra, E., & Liberopoulos, E. (2025). The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review. Journal of Atherosclerosis Prevention and Treatment, 16(3), 93-98. https://doi.org/10.4103/aptj.aptj_16_25

Vancouver

Blathra E, Liberopoulos E. The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review. Journal of Atherosclerosis Prevention and Treatment. 2025;16(3):93-98. doi:10.4103/aptj.aptj_16_25

BibTeX
@article{Blathra2025,
  author = {Blathra, Effrosyni and Liberopoulos, Evangelos},
  title = {The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review},
  journal = {Journal of Atherosclerosis Prevention and Treatment},
  year = {2025},
  volume = {16},
  number = {3},
  pages = {93--98},
  doi = {10.4103/aptj.aptj_16_25}
}
Kostenlos starten →